Li, J, Lou, Z, Liu, X, Sun, Y, Chen, J. Efficacy and safety of adjuvant treatment with entacapone in advanced Parkinson’s disease with motor fluctuation: a systematic meta-analysis. Eur Neurol 2017; 78(3–4): 143–153.CrossRefGoogle ScholarPubMed

Müller, T. Entacapone. Expert Opin Drug Metab Toxicol 2010; 6(8): 983–993.CrossRefGoogle ScholarPubMed

Schrag, A. Entacapone in the treatment of Parkinson’s disease. Lancet Neurol 2005; 4(6): 366–370.CrossRefGoogle ScholarPubMed

AHFS Drug information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 17 June 2021 via www.medicinescomplete.com.Google Scholar

Brooks, DJ, Sagar, H.. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 2003; 74(8): 1071–1079.CrossRefGoogle ScholarPubMed

Brusa, L, Bassi, A, Lunardi, G, Fedele, E, Peppe, A, Stefani, A, Pasqualetti, P, Stanzione, P, Pierantozzi, M. Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug. Eur J Neurol 2004; 11(9): 593–606.CrossRefGoogle ScholarPubMed

Entacapone. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 17 June 2022 via www.medicinescomplete.com.Google Scholar

Entacapone. In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed on 3 March 2023 via www.micromedexsolutions.com.Google Scholar

Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 17 June 2022 via www.medicinescomplete.com.Google Scholar

Larsen, JP, Worm-Petersen, J, Sidén, A, Gordin, A, Reinikainen, K, Leinonen, M. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson’s disease. Eur J Neurol 2003; 10(2): 137–146.CrossRefGoogle ScholarPubMed

Olanow, CW, Kieburtz, K, Stern, M, Watts, R, Langston, JW, Guarnieri, M, Hubble, J. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol 2004; 61(10): 1563–1568.CrossRefGoogle Scholar

Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Ann Neurol 1997; 42(5): 747–755.CrossRefGoogle Scholar

Poewe, WH, Deuschl, G, Gordin, A, Kultalahti, ER, Leinonen, M. Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002; 105(4): 245–255.CrossRefGoogle ScholarPubMed

Rinne, UK, Larsen, JP, Siden, A, Worm-Petersen, J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998; 51(5): 1309–1314.CrossRefGoogle ScholarPubMed

Summary of product characteristics – Comtess 200 mg film-coated tablets. Orion Pharma (UK) Ltd. Electronic Medicines Compendium: Comtess 200 mg film-coated tablets – Summary of product characteristics (SmPC) – (emc). Accessed on 3 March 2023 via www.medicines.org.uk.Google Scholar